About

This event is free for executive-level biotech leaders and is organized by the following event partners – Association of University Research Parks, AstraZeneca, BioHealth Innovation, BRAINBox Solutions, Inc, Children’s National Hospital, Emergent BioSolutions, George Mason University, Johnson & Johnson Innovation – JLABS @ Washington, DC, Maryland Department of Commerce, and Virginia Bio.

NOTE: This even will be a hybrid in-person and live streaming event on September 20th from the offices of United States Pharmacopeia in Rockville, Maryland.

Register and live viewing information to come soon!

2022 Agenda

  • Welcoming Remarks – MD/VA/Mont. County
  • Imagine the Future Together
  • GEN Top 10 BioCluster Update
  • BioHealth Capital Region Update
  • Global Pandemic Prevention & BioDefense Center

Networking Break

  • Healthcare Innovation and Change – Fireside Chat
  • Infectious Diseases Resources for Research and Development
  • US Pharmacopeia Introduction

Lunch Break

  • The FDA Centers for Regulatory Science and Innovation
  • Regional Support for BioHealth Entrepreneurs
  • Stewardship & Sustainability in the BioHealth Industry
  • ARPA- H
  • Innovation through Collaboration: Opportunities in the BHCR
  • BioHealth Investment Climate
  • Maurice Jones/Diversity Equity and Inclusion – Keynote
  • Closing Remarks

Don’t miss your chance to be named the BioHealth Startup with the Most Commercial Potential at the BHCR Forum, win a cash prize, clinical research services and more!

Visit https://bit.ly/CrabTrap2022 to apply today!

Previous Crab Trap Winners

2021 – NanoChon
Nanochon is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
2020 – BrainScope
BrainScope is a developer of a non-invasive medical device intended to objectively assess head-injured patients for both brain bleeds & concussions at point of care. The company’s device is FDA-cleared, portable, EEG-based, assessment tool that empowers physicians to quickly triage patients for brain bleeds, concussion and the need for a CT scan, providing healthcare professionals with objective diagnostic insights that enable better patient care. The company is reportedly in the process of raising $15 million of venture funding on March 25, 2021. The funds will be used to speed up and expand the company’s commercial execution. Previously, The company was approved for a Paycheck Protection Program Loan for $1.07 million from Sandy Spring Bank on April 09, 2020. The application cited 40 jobs to be retained with the financing.
2019 – Floreo Inc.
Floreo is a developer of a learning platform designed to build a new generation of training program for people with autism and other developmental challenges. The company’s platform leverages the power of virtual reality to develop a supplementary method of teaching social and communication skills, enabling individuals with an autism spectrum disorder to build real-world skills. The company was approved for a Paycheck Protection Program Loan in the range of $150,000-350,000 from Wells Fargo Bank, National Association on May 3, 2020. The application cited jobs to be retained with the financing.
2018 – Galen Robotics
Galen Robotics, is a developer of a surgical robot designed to aid surgeons across several disciplines with minimal disturbance to existing workflows. The company’s robot is designed to assist doctors in executing precise movements with certain surgical instruments, while reducing risks from hand shakiness, enabling surgeons to make minimally invasive interventions safer, faster and more precise. The company is reportedly seeking $25 million of Series A venture funding from undisclosed investors as of March 19, 2021. Previously, the company raised $7 million of seed funding from Verte Capital, TEDCO and Maryland Department of Commerce on November 6, 2020.
2017 – LifeSprout
LifeSprout is a Developer of synthetic soft tissue substitutes intended to be used for aesthetic and reconstructive medicine in tissue reproduction. The company’s tissue substitutes focus on regrowth human tissue by transferring tissue from one part of the body to another, enabling doctors to repair patients’ soft tissue damage from trauma, natural aging, surgery, cancer and metabolic disease.
2016 –  Sonavex

Sonavex, a medical device company intended to create novel and automated ultrasound technology. The company has developed a portfolio of novel ultrasound solutions to visualize and quantify critical clinical data for improved outcomes and reduced costs in new surgical applications, empowering clinicians with actionable data to deliver superior patient care and deliver savings to the healthcare system.